Learning Disability Treatment Market By Therapy (Stimulant Medication, Non Stimulant Medication, Orton-Gillingham Interventional Therapy, Occupational Therapy, Assistive Technology), By Indication (Attention Deficit Hyperactivity Disorder (ADHD), Dyslexia, Dyspraxia, Others) - Growth, Future Prospects & Competitive Analysis, 2019 – 2027

Industry Outlook

The learning disability treatment market is set to reach US$ 30,493.1 Mn by 2027 from US$ 17,418.0 Mn in 2018 highlighting steady growth at a compounded annual growth rate (CAGR) of 6.5% during the forecast period from 2019 to 2027.  Children with learning disability have tremendous mental ability but due to irregular impulses generated by the central nervous system they suffer with altered behavior and lower cognitive skills. If diagnosed at an early stage with proper medical intervention will improve the quality of life of the patient suffering with learning disability.

Market Synopsis

Get a sample copy for more information

"Excellent therapeutic efficacy and rising popularity among psychiatrist drive the demand for stimulant and non stimulant medication"

Stimulant and non-stimulant medication are leading the therapy segment for learning disability treatment market. Psychoactive drugs such as Ritalin, Focalin, Dexedrin and Vynase are prescribed for improving the central nervous system activity by blocking the uptake of catecholamines such as dopamine and norepinephrine. Non stimulants are also prescribed to treat depression and anxiety encountered in few patients suffering with ADHD. Assistive technology is gaining huge traction owing to its ability to provide cognitive behavioral therapy and occupational therapy in the form of learning applications and software to aid teachers in helping kids with dyslexia and dyspraxia.

Get a sample copy for more information

"Comprehensive evaluation test and critical assessment of underlying language skills results in early diagnosis of dyslexia"

Dyslexia is reigning the indication segment for learning disability treatment market. According to the research findings brought forward by International Dyslexia Association (IDA), the prevalence rate of dyslexia in children qualifying for special education is 6-7%. The core problem associated with dyslexia is difficulty in word recognition, reading and writing fluency etc. Comprehensive evaluation test and critical assessment of underlying language skills results in early diagnosis of dyslexia and interventional therapy. Attention deficit hyperactivity disorder (ADHD), has a worldwide prevalence rate of 2.2%, with high occurrence in male in comparison to female. Effective clinical guidelines have been designed by psychiatrist worldwide with effective combination of pharmacological drugs and occupational and cognitive behavioral therapy for the effective treatment of ADHD.

Get a sample copy for more information

"Rising prevalence of ADHD and proactive government initiatives to promote awareness and treatment for mentally disabled childrens drives the market growth in North America"

North America is presently dominating the regional segment for learning disability treatment market holding a market share of 32.5%. The major factor responsible for its outstanding market growth are rising prevalence of attention deficit hyperactivity disorder (ADHD), as per the statistics provided by the American Psychiatric Association (APA) in 2016, approximately 6.1 million children were diagnosed with ADHD in North America. Proactive government initiatives to promote awareness and treatment for mentally disabled children further bolster the market growth. Europe represents 29% market share on account of rising prevalence of dyslexia across all age group. According to the research findings of European Dyslexia Association (EDA), the prevalence rate of dyslexia is between 9 to 12% of the population. Asia Pacific holds 18.5% market share owing to the rampant growth in schools and institutes to treat children with learning disabilities and significant rise in assistive technology focusing on the development of learning software and applications in compliance with occupational therapy.

Historical & Forecast Period

This research report presents the analysis of each segment from 2017 to 2027 considering 2018 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

The market segmentation for the scope of report is done as by therapy, indication and geography.

IT-Healthcare in collaboration with pharmaceutical companies actively participating in the learning disability treatment market are CogniFit, Eli Lilly & Company, Forest Laboratories, Inc., IMSE, Novartis AG, Pfizer, Inc., Shire, Plc., Therapro, Inc., Tumble N’ Dots, Inc. and Texthelp Ltd.

Key questions answered in this report

• Which pharmaceutical companies are actively engaged in the learning disability treatment market?
• What are the DRO’s associated with learning disability treatment market?
• What is the prevalence rate of different kinds of learning disabilities?
• Which is the disease etiology of ADHD and medication prescribed by psychiatrist for its treatment?
• What is the market share and CAGR of non pharmacological medical intervention utilized in learning disability treatment?
• What will be the market performance in North America and Asia Pacific region?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global LDT Market Portraiture
2.2. Global LDT Market, by Therapy, 2018 (US$ Mn)
2.3. Global LDT Market, by Indication, 2018 (US$ Mn)
2.4. Global LDT Market, by Geography, 2018 (US$ Mn)

Chapter 3. Learning Disability Treatment (LDT) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2018
3.6. Competitive Analysis: Global LDT Market, by Key Players, 2018

Chapter 4. Global Learning Disability Treatment (LDT) Market, by Therapy
4.1. Overview
4.2. Stimulant Medication
4.3. Non Stimulant Medication
4.4. Orton-Gillingham Interventional Therapy
4.5. Occupational Therapy
4.6. Assistive Technology

Chapter 5. Global Learning Disability Treatment (LDT) Market, by Indication
5.1. Overview
5.2. Attention Deficit Hyperactivity Disorder (ADHD)
5.3. Dyslexia
5.4. Dyspraxia
5.5. Others

Chapter 6. Global Learning Disability Treatment (LDT) Market, by Geography
6.1. Overview
6.2. North America LDT Market Analysis, 2017 – 2027
6.2.1. North America LDT Market, by Therapy, 2017 – 2027 (US$ Mn)
6.2.2. North America LDT Market, by Indication, 2017 – 2027 (US$ Mn)
6.2.3. North America LDT Market, by Country, 2017 – 2027 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe LDT Market Analysis, 2017 – 2027
6.3.1. Europe LDT Market, by Therapy, 2017 – 2027 (US$ Mn)
6.3.2. Europe LDT Market, by Indication, 2017 – 2027 (US$ Mn)
6.3.3. Europe LDT Market, by Country/Region, 2017 – 2027 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific LDT Market Analysis, 2017 – 2027
6.4.1. Asia Pacific LDT Market, by Therapy, 2017 – 2027 (US$ Mn)
6.4.2. Asia Pacific LDT Market, by Indication, 2017 – 2027 (US$ Mn)
6.4.3. Asia Pacific LDT Market, by Country/Region, 2017 – 2027 (US$ Mn)
6.4.3.1. China
6.4.3.2. Japan
6.4.3.3. Rest of Asia Pacific
6.5. Latin America LDT Market Analysis, 2017– 2027
6.5.1. Latin America LDT Market, by Therapy, 2017 – 2027 (US$ Mn)
6.5.2. Latin America LDT Market, by Indication, 2017 – 2027 (US$ Mn)
6.5.3. Latin America LDT Market, by Country/Region, 2017 – 2027 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East and Africa LDT Market Analysis, 2017 – 2027
6.6.1. MEA LDT Market, by Therapy, 2017 – 2027 (US$ Mn)
6.6.2. MEA LDT Market, by Indication, 2017 – 2027 (US$ Mn)
6.6.3. MEA LDT Market, by Country/Region, 2017 – 2027 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. Eli Lilly & Company
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. CogniFit
7.3. Forest Laboratories, Inc.
7.4. IMSE
7.5. Novartis AG
7.6. Pfizer, Inc.
7.7. Shire, Plc.
7.8. Therapro, Inc.
7.9. Tumble N’ Dots, Inc.
7.10. Texthelp Ltd.

* Here we are using LDT as a short form of Learning Disability Treatment

FIG. 1 Learning Disability Treatment (LDT) Market: Research Methodology
FIG. 2 LDT: Market Segmentation
FIG. 3 Global LDT Market, by Therapy, 2018 (US$ Mn)
FIG. 4 Global LDT Market, by Indication, 2018 (US$ Mn)
FIG. 5 Global LDT Market, by Geography, 2018 (US$ Mn)
FIG. 6 Attractive Investment Proposition: by Geography, 2018
FIG. 7 Competitive Analysis: Global LDT Market, by Key Players, 2018
FIG. 8 Global Stimulant Medication Market for LDT, 2017 – 2027 (US$ Mn)
FIG. 9 Global Non Stimulant Medication Market for LDT, 2017 – 2027 (US$ Mn)
FIG. 10 Global Orton-Gillingham Interventional Therapy Market for LDT, 2017 – 2027 (US$ Mn)
FIG. 11 Global Occupational Therapy Market for LDT, 2017 – 2027 (US$ Mn)
FIG. 12 Global Assistive Technology Market for LDT, 2017 – 2027 (US$ Mn)
FIG. 13 Global ADHD Market for LDT, 2017 – 2027 (US$ Mn)
FIG. 14 Global Dyslexia Market for LDT, 2017 – 2027 (US$ Mn)
FIG. 15 Global Dyspraxia Market for LDT, 2017 – 2027 (US$ Mn)
FIG. 16 Global Other Indications Market for LDT, 2017 – 2027 (US$ Mn)
FIG. 17 U.S. LDT Market, 2017 – 2027 (US$ Mn)
FIG. 18 Canada LDT Market, 2017 – 2027 (US$ Mn)
FIG. 19 U.K. LDT Market, 2017 – 2027 (US$ Mn)
FIG. 20 Germany LDT Market, 2017 – 2027 (US$ Mn)
FIG. 21 Rest of Europe LDT Market, 2017 – 2027 (US$ Mn)
FIG. 22 China LDT Market, 2017 – 2027 (US$ Mn)
FIG. 23 Japan LDT Market, 2017 – 2027 (US$ Mn)
FIG. 24 Rest of Asia Pacific LDT Market, 2017 – 2027 (US$ Mn)
FIG. 25 Brazil LDT Market, 2017 – 2027 (US$ Mn)
FIG. 26 Mexico LDT Market, 2017 – 2027 (US$ Mn)
FIG. 27 Rest of Latin America LDT Market, 2017 – 2027 (US$ Mn)
FIG. 28 GCC LDT Market, 2017 – 2027 (US$ Mn)
FIG. 29 Rest of MEA LDT Market, 2017 – 2027 (US$ Mn)

TABLE 1 Global Learning Disability Treatment (LDT) Market Portraiture
TABLE 2 Global LDT Market, by Therapy, 2017 – 2027 (US$ Mn)
TABLE 3 Global LDT Market , by Indication, 2017 – 2027 (US$ Mn)
TABLE 4 Global LDT Market, by Geography, 2017 – 2027 (US$ Mn)
TABLE 5 North America LDT Market, by Therapy, 2017 – 2027 (US$ Mn)
TABLE 6 North America LDT Market, by Indication, 2017 – 2027 (US$ Mn)
TABLE 7 North America LDT Market, by Country, 2017 – 2027 (US$ Mn)
TABLE 8 Europe LDT Market, by Therapy, 2017 – 2027 (US$ Mn)
TABLE 9 Europe LDT Market, by Indication, 2017 – 2027 (US$ Mn)
TABLE 10 Europe LDT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 11 Asia Pacific LDT Market, by Therapy, 2017 – 2027 (US$ Mn)
TABLE 12 Asia Pacific LDT Market, by Indication, 2017 – 2027 US$ Mn)
TABLE 13 Asia Pacific LDT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 14 Latin America LDT Market, by Therapy, 2017 – 2027 (US$ Mn)
TABLE 15 Latin America LDT Market, by Indication, 2017 – 2027 (US$ Mn)
TABLE 16 Latin America LDT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 17 Middle East and Africa LDT Market, by Therapy, 2017 – 2027 (US$ Mn)
TABLE 18 Middle East and Africa LDT Market, by Indication, 2017 – 2027 (US$ Mn)
TABLE 19 Middle East and Africa LDT Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 20 Eli Lilly & Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 CogniFit: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Forest Laboratories, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 IMSE: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 Shire, Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 Therapro, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 28 Tumble N’ Dots, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 Texthelp Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)